16434-24-5

Upstream product

• 26151-89-3 methyl 2-(4-hydroxy-3-methoxybenzylidene)hydrazine-1-carbodithioate 
• 106-47-8 4-chloro-aniline 
• 22814-92-2 4-(p-chlorophenyl)-3-thiosemicarbazide 
• 121-33-5 vanillin 
• 2131-55-7 4-Chlorophenyl isothiocyanate 

Downstream Products

• 1300713-16-9 2-(3-methoxy-4-hydroxyphenyl)-5-(4-chloro-phenylamino)-1,3,4-thiadiazole 
• 1380075-04-6 N¹-4-chlorobenzylidene-N²-[3-(4-hydroxy-3-methoxyphenyl)-4-(2,5-dihydroxyphenyl)-1,3-thiazol-2-ylidene]hydrazine 
• 1380075-18-2 N¹-4-chlorobenzylidene-N²-[3-(4-hydroxy-3-methoxyphenyl)-4-(1,4-benzoquinon-2-yl)-1,3-thiazol-2-ylidene]hydrazine 

Relevant academic research and scientific papers

Synthesis and in vitro anti-toxoplasma gondii activity of novel thiazolidin-4-one derivatives

Recent findings on the biological activity of thiazolidin-4-ones and taking into account the lack of effective drugs used in the treatment of toxoplasmosis, their numerous side effects, as well as the problem of drug resistance of parasites prompted us to

Synthesis and biological evaluation of novel benzoquinones as potential antimicrobial agents

New series of 2,5-dihydroxyphenyl-1,3-thiazoles 4a-l was synthesized by reacting 2,5-dihydroxyphenacyl bromide with various 4-aryl thiosemicarbazones 3a-l that on oxidation with ferric chloride yielded the corresponding N 1-substituted benzylid

One-pot synthesis and anticancer studies of 2-arylamino-5-aryl-1,3,4- thiadiazoles

A series of 2-arylamino-5-aryl-1,3,4-thiadiazoles 1a-j were synthesized and screened for their anticancer activity against various human cancer cell lines. The novel one-pot synthesis of 1,3,4-thiadiazoles was achieved by refluxing aryl aldehydes, hydrazi

Synthesis and Ribonucleotide reductase inhibitory activity of thiosemicarbazones

Ribonucleotide reductase (RR) is an important therapeutic target for anticancer drugs. The structure of human RR features a 1:1 complex of two homodimeric subunits, hRRM1 and hRRM2. Prokaryotically expressed and highly purified recombinant human RR subunits, hRRM1 and hRRM2, were used for holoenzyme-based [3H]CDP reduction in vitro assay. Ten new thiosemicarbazones (7-16) were synthesized and screened for their RR inhibitory activity. Two thiosemicarbazones derived from p-hydroxy benzaldehyde (9 and 10) were found to be active but less potent than the standard, Hydroxyurea (HU). Guided by the activity of compounds 9 and 10, 11 new thiosemicarbazones (17-27) derived from p-hydroxy benzaldehyde were prepared and screened for their RR inhibitory activity. All the 11 compounds were more potent than HU.